
USD
$0.00
(0.00%
)At Close (As of Oct 24, 2025)
$12.14B
Market Cap
18.23
P/E Ratio
0.8
EPS
$16.07
52 Week High
$12.18
52 Week Low
HEALTHCARE
Sector
| Field | Value (INR) |
|---|---|
| Gross Profit | $190B |
| Total Revenue | $326B |
| Cost Of Revenue | $135B |
| Costof Goods And Services Sold | $135B |
| Operating Income | $72B |
| Selling General And Administrative | $94B |
| Research And Development | $27B |
| Operating Expenses | $119B |
| Investment Income Net | - |
| Net Interest Income | -$152M |
| Interest Income | $2.7B |
| Interest Expense | $2.8B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $17B |
| Income Before Tax | $77B |
| Income Tax Expense | $20B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $57B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $80B |
| Ebitda | $97B |
| Net Income | $57B |
| Field | Value (INR) |
|---|---|
| Total Assets | $493B |
| Total Current Assets | $250B |
| Cash And Cash Equivalents At Carrying Value | $15B |
| Cash And Short Term Investments | $15B |
| Inventory | $71B |
| Current Net Receivables | $110B |
| Total Non Current Assets | $243B |
| Property Plant Equipment | $97B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $97B |
| Intangible Assets Excluding Goodwill | $97B |
| Goodwill | $12B |
| Investments | - |
| Long Term Investments | $15B |
| Short Term Investments | $43B |
| Other Current Assets | $11B |
| Other Non Current Assets | - |
| Total Liabilities | $156B |
| Total Current Liabilities | $130B |
| Current Accounts Payable | $20B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $39B |
| Total Non Current Liabilities | $25B |
| Capital Lease Obligations | $4.9B |
| Long Term Debt | $3.8B |
| Current Long Term Debt | $38B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $47B |
| Other Current Liabilities | $66B |
| Other Non Current Liabilities | $2.1B |
| Total Shareholder Equity | $333B |
| Treasury Stock | - |
| Retained Earnings | $316B |
| Common Stock | $834M |
| Common Stock Shares Outstanding | $834M |
| Field | Value (INR) |
|---|---|
| Operating Cashflow | $46B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $17B |
| Capital Expenditures | $34B |
| Change In Receivables | - |
| Change In Inventory | -$13B |
| Profit Loss | - |
| Cashflow From Investment | -$58B |
| Cashflow From Financing | $19B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $6.7B |
| Dividend Payout Common Stock | $6.7B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1.4B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $57B |
| Field | Value (INR) |
|---|---|
| Gross Profit | $190B |
| Total Revenue | $326B |
| Cost Of Revenue | $135B |
| Costof Goods And Services Sold | $135B |
| Operating Income | $72B |
| Selling General And Administrative | $94B |
| Research And Development | $27B |
| Operating Expenses | $119B |
| Investment Income Net | - |
| Net Interest Income | -$152M |
| Interest Income | $2.7B |
| Interest Expense | $2.8B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $17B |
| Income Before Tax | $77B |
| Income Tax Expense | $20B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $57B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $80B |
| Ebitda | $97B |
| Net Income | $57B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-07-25 |
| Declaration Date | 2025-06-30 |
| Record Date | 2025-07-10 |
| Payment Date | 2025-08-06 |
| Amount | 0.091485 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Dr. Reddy's Laboratories Ltd (ADR) is a leading global pharmaceutical company based in Hyderabad, India, known for its comprehensive portfolio of generic medicines, proprietary drugs, and active pharmaceutical ingredients. With a strong focus on research and development, Dr. Reddy's fosters innovation across various therapeutic segments while maintaining a robust supply chain to serve markets worldwide. The company's commitment to providing high-quality, affordable healthcare solutions underlines its strategic vision in the pharmaceutical landscape, positioning it as a key player in both emerging and developed markets.